title: Characterization of hematopoietic stem cell subsets from patients with multiple myeloma after mobilization with plerixafor.
abstract: OBJECTIVE
  Previous studies have demonstrated that the combination of granulocyte-colony-stimulating factor (G-CSF) + plerixafor is more efficient in mobilizing CD34(+) hematopoietic stem cells (HSC) into the peripheral blood than G-CSF alone. In this study we analyzed the impact of adding plerixafor to G-CSF upon the mobilization of different HSC subsets.
  
  
  METHODS
  We characterized the immunophenotype of HSC subsets isolated from the peripheral blood of eight patients with multiple myeloma (MM) before and after treatment with plerixafor. All patients were supposed to collect stem cells prior to high-dose chemotherapy and consecutive autologous stem cell transplantation, and therefore received front-line mobilization with 4 days of G-CSF followed by a single dose of plerixafor. Samples of peripheral blood were analyzed comparatively by flow cytometry directly before and 12 h after administration of plerixafor.
  
  
  RESULTS
  The number of aldehyde dehydrogenase (ALDH)(bright) and CD34(+) cells was significantly higher after plerixafor treatment (1.2-5.0 and 1.5-6.0 times; both P < 0.01) and an enrichment of the very primitive CD34(+) CD38(-) and ALDH(bright) CD34(+) CD38(-) HSC subsets was detectable. Additionally, two distinct ALDH(+) subsets could be clearly distinguished. The small ALDH(high) subset showed a higher number of CD34(+) CD38(-) cells in contrast to the total ALDH(bright) subpopulation and probably represented a very primitive subpopulation of HSC.
  
  
  CONCLUSIONS
  A combined staining of ALDH, CD34 and CD38 might represent a powerful tool for the identification of a very rare and primitive hematopoietic stem cell subset. The addition of plerixafor mobilized not only more CD34(+) cells but was also able to increase the proportion of more primitive stem cell subsets.
authors.affiliation: Department of Medicine V, Heidelberg University, Heidelberg, Germany.
authors.forename: Isabel
authors.initials: I
authors.lastname: Taubert
authors.forename: Rainer
authors.initials: R
authors.lastname: Saffrich
authors.forename: Abraham
authors.initials: A
authors.lastname: Zepeda-Moreno
authors.forename: Isabelle
authors.initials: I
authors.lastname: Hellwig
authors.forename: Volker
authors.initials: V
authors.lastname: Eckstein
authors.forename: Thomas
authors.initials: T
authors.lastname: Bruckner
authors.forename: Anthony D
authors.initials: AD
authors.lastname: Ho
authors.forename: Patrick
authors.initials: P
authors.lastname: Wuchter
mesh_terms: D000368:Aged; D001596:Benzylamines; D002478:Cells, Cultured; D000080027:Cyclams; D005260:Female; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D006412:Hematopoietic Stem Cells / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism; D006571:Heterocyclic Compounds / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000378:metabolism / Q000473:pathology*; D016133:Polymerase Chain Reaction; D019718:Receptors, CXCR4 / Q000037:antagonists & inhibitors
chemical_list: D001596:Benzylamines; D000080027:Cyclams; D006571:Heterocyclic Compounds; D019718:Receptors, CXCR4; C088327:plerixafor